Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 11;8(9):1436.
doi: 10.3390/jcm8091436.

Serum Secretogranin III Concentrations Were Increased in Subjects With Metabolic Syndrome and Independently Associated With Fasting Plasma Glucose Levels

Free PMC article

Serum Secretogranin III Concentrations Were Increased in Subjects With Metabolic Syndrome and Independently Associated With Fasting Plasma Glucose Levels

Chun-Chung Lin et al. J Clin Med. .
Free PMC article


Secretogranin III (SCG3) plays a crucial role in the biogenesis of secretory granules in endocrine cells, and thus affects glucose homeostasis by regulating insulin secretion by pancreatic beta cells. Insulin resistance and compensatory hyperinsulinemia are hallmarks of metabolic syndrome (MetS). However, the role of SCG3 in MetS remains unclear. Therefore, we investigated the relationship between serum SCG3 levels and metabolic parameters in subjects with and without MetS. This was a case control study, and 295 subjects were recruited. Serum SCG3 concentrations were compared between groups. Associations between SCG3 levels and clinico-metabolic parameters were also examined. We found serum SCG3 levels were higher in the MetS group than non-MetS group (122.6 ± 79.2 vs. 90.6 ± 58.5 nmol/L, p = 0.009). Specifically, elevated SCG3 levels were found in subjects with high fasting plasma glucose (FPG) levels, central obesity, or hypertriglyceridemia. Additionally, MetS was an independent factor of serum SCG3 levels in multivariate linear regression analyses. Moreover, FPG, free fatty acids, and waist circumference were positively associated with serum SCG3 concentrations after adjusting for insulin levels, high-sensitivity C-reactive protein, and cardiovascular risk factors. In conclusion, serum SCG3 concentrations were higher in subjects with MetS and were independently associated with FPG levels.

Keywords: free fatty acid; hyperglycemia; metabolic syndrome; obesity; secretogranin III.

Conflict of interest statement

The authors declare no conflict of interest.


Figure 1
Figure 1
Comparison of serum secretogranin III levels between subjects without and those with metabolic syndrome (MetS).
Figure 2
Figure 2
Comparisons of serum secretogranin III levels between subjects with/without each component of metabolic syndrome.

Similar articles

See all similar articles

Cited by 1 article


    1. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404. - DOI - PubMed
    1. Saklayen M.G. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep. 2018;20:12. doi: 10.1007/s11906-018-0812-z. - DOI - PMC - PubMed
    1. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., Montori V.M. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 2007;49:403–414. doi: 10.1016/j.jacc.2006.09.032. - DOI - PubMed
    1. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care. 2005;28:1769–1778. doi: 10.2337/diacare.28.7.1769. - DOI - PubMed
    1. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 1995;75:473–486. doi: 10.1152/physrev.1995.75.3.473. - DOI - PubMed